Corient Private Wealth
ALNY icon

Corient Private Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

Corient Private Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.22M Sell
23,969
-1,749
-7% -$528K 0.01% 751
2026
Q1 		$8.5M Buy
25,718
+1,955
+8% +$665K 0.01% 673
2025
Q4 		$9.45M Sell
23,763
-15,629
-40% -$6.92M 0.01% 579
2025
Q3 		$18M Sell
39,392
-2,760
-7% -$1.12M 0.03% 407
2025
Q2 		$13.7M Sell
42,152
-513
-1% -$142K 0.02% 457
2025
Q1 		$11.5M Sell
42,665
-235,901
-85% -$60.6M 0.02% 493
2024
Q4 		$65.5M Buy
278,566
+81
+0% +$21.3K 0.11% 183
2024
Q3 		$76.6M Buy
278,485
+3,749
+1% +$976K 0.12% 174
2024
Q2 		$66.8M Buy
274,736
+129
+0% +$20.4K 0.12% 180
2024
Q1 		$41M Sell
274,607
-89
-0% -$14.8K 0.07% 259
2023
Q4 		$52.6M Buy
274,696
+1,579
+0.6% +$269K 0.1% 213
2023
Q3 		$48.4M Buy
273,117
+588
+0.2% +$112K 0.11% 194
2023
Q2 		$51.8M Sell
272,529
-353
-0.1% -$70K 0.12% 177
2023
Q1 		$54.7M Buy
272,882
+270,010
+9,401% +$56.8M 0.15% 153
2022
Q4 		$683K Buy
+2,872
New +$613K ﹤0.01% 1044

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Corient Private Wealth's ALNY Position: Q2 2026 in Review

Corient Private Wealth reduced its Alnylam Pharmaceuticals (ALNY) stake by 6.8% in Q2 2026, selling an estimated $528K and leaving 23,969 shares worth $7.22M. The position accounts for 0.01% of the portfolio, ranked #751.

Corient Private Wealth first reported a position in ALNY in Q4 2022 and has held it in 15 quarters since. The position peaked at $76.6M in Q3 2024. 789 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Corient Private Wealth held 23,969 shares of Alnylam Pharmaceuticals worth $7.22M as of Q2 2026.
  • Corient Private Wealth sold 1,749 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $528K.
  • Alnylam Pharmaceuticals made up 0.01% of Corient Private Wealth's portfolio in Q2 2026, its #751 holding.
  • Corient Private Wealth first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Corient Private Wealth's Alnylam Pharmaceuticals position peaked at $76.6M in Q3 2024.
  • 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.